Erasca Reports Third Quarter 2026 Business Updates and Financial Results
ERAS-0015 granted FDA Fast Track Designation for metastatic pancreatic adenocarcinoma; advancing toward three potentially registration-enabling trials in pancreatic and lung cancers
Covered in this story
Call it yourself
No calls on $ERAS yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Erasca Inc →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.